The National Cancer Institute's Urologic Oncology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize detection methods to screen a biomarker for renal cancer.
Birt-Hogg-Dube' (BHD) syndrome is a potentially disfiguring dermatologic disorder associated with an increased risk for developing renal cancer, spontaneous pneumothorax and lung cysts. This invention describes the identification and characterization of a FNIP1 homolog, folliculin-interacting protein 2 (FNIP2), that interacts with folliculin. Folliculin is the protein encoded by the FLCN gene, which is responsible for the Birt-Hogg-Dube (BHD) syndrome. Folliculin interacts with AMPK, an important energy sensor in cells and negative regulator of mTOR, through its binding partners FNIP1 and FNIP2, suggesting FNIP2 may play a role in sensing cellular energy deficit. Importantly, FNIP2 expression was elevated in renal tumors seen in BDH patients. This finding suggests that FNIP2 may serve as a biomarker for BHD. Additionally, this technology could facilitate the development of therapeutic drugs to treat the skin lesions and renal tumors that develop in BHD patients.
Further R&D Needed:
R&D Status: Pre-clinical development
IP Status: This invention is classified as a Research Tool, and patent protection is not being sought pursuant to NIH patent policy.
John D. Hewes, Ph.D.
NCI Technology Transfer Center
Please reference advertisement #757
Last updated 2/9/2012
This opportunity is also listed under the following categories: